Blog
RSS FeedPosted by Michael Wonder on 28 Feb 2022
Schedule of Pharmaceutical Benefits - 1 March 2022
1 March 2022 - The March 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 28 Feb 2022
New treatment for Australians with rare blood disease
28 February 2022 - Australians with paroxysmal nocturnal haemoglobinuria—a condition that produces defective blood cells—will have access to a new treatment ...
Posted by Michael Wonder on 26 Feb 2022
Landmark PBS listing for Australians with leukaemia
25 February 2022 - From 1 March 2022, Australians with acute myeloid leukaemia will have access to a new treatment option ...
Posted by Michael Wonder on 31 Jan 2022
Schedule of Pharmaceutical Benefits - 1 February 2022 update
1 February 2022 - The February 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Jan 2022
New Zealand Pharmaceutical Schedule - 1 February 2022 update
1 February 2022 - The Febuary 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Jan 2022
Baqsimi (nasal glucagon) rescue treatment for severe hypoglycaemia now covered in Ontario
28 January 2022 - Lilly Canada is pleased to announce that as of 31 January 2022, Baqsimi (glucagon nasal powder) ...
Posted by Michael Wonder on 30 Jan 2022
PBS listing to benefit Australians with rare type of non-Hodgkin lymphoma
31 January 2022 - From 1 February, thousands of Australians with a relapsed and/or refractory mantle cell lymphoma, a form of ...
Posted by Michael Wonder on 24 Jan 2022
Australians with severe dermatitis to benefit from PBS listing
24 January 2022 - From 1 February 2022, Australians with severe atopic dermatitis will have access to a new treatment ...
Posted by Michael Wonder on 23 Jan 2022
Thousands to benefit from decision to subsidise eczema treatment
23 January 2022 - Australians suffering from a severe form of eczema will save tens of thousands of dollars after a ...
Posted by Michael Wonder on 17 Jan 2022
PHARMAC - 2021 in review
17 January 2022 - PHARMAC released its Year in Review for 2021 in late December. ...
Posted by Michael Wonder on 31 Dec 2021
Schedule of Pharmaceutical Benefits - 1 January 2022 update
1 January 2022 - The January 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Dec 2021
New Zealand Pharmaceutical Schedule - 1 January 2022
1 January 2022 - The January 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Dec 2021
PBS listing for Braftovi and cetuximab for metastatic bowel cancer patients with BRAFV600 mutation
30 December 2021 - Pierre Fabre Australia today announced that Braftovi (encorafenib) in combination with cetuximab will be listed on the ...
Posted by Michael Wonder on 20 Dec 2021
New treatment for heart failure to support thousands of Australian patients
20 December 2021 - From 1 January 2022, tens of thousands of Australians with symptomatic heart failure will have access to ...
Posted by Michael Wonder on 07 Dec 2021
Biosimilar follitropin alfa on the PBS - information for health care professionals and patients
7 December 2021 - A biosimilar brand of follitropin alfa (Ovaleap) was listed on the PBS on 1 December 2021. ...